Multimodal Treatment Study of Children With Attention Deficit and Hyperactivity Disorder (MTA)
Launched by NYU LANGONE HEALTH · Nov 2, 1999
Trial Information
Current as of May 09, 2025
Completed
Keywords
ClinConnect Summary
This trial is a continuation of the Multimodal Treatment Study of Children with Attention Deficit Hyperactivity Disorder (MTA Study). Continuation Aim 1 is to track the persistence of intervention-related effects as the MTA sample matures into mid-adolescence, including subsequent mental-health and school-related service utilization patterns as a function of MTA treatment experience (treatment assignment) and outcome (degree of treatment success at 14 mo.). Aim 2 is to test specific hypotheses about predictors, mediators, and moderators of long-term outcome among children with ADHD (e.g., c...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • -
- Patients must have:
- • Rigorously diagnosed Attention Deficit Hyperactivity Disorder (ADHD).
About Nyu Langone Health
NYU Langone Health is a premier academic medical center located in New York City, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a leading sponsor of clinical trials, NYU Langone Health integrates cutting-edge scientific inquiry with patient-centered care, striving to develop new therapies and improve health outcomes across a wide range of medical conditions. The institution is dedicated to fostering collaboration among researchers, clinicians, and patients, ensuring rigorous adherence to ethical standards and regulatory guidelines in all clinical research initiatives. By leveraging its extensive resources and expertise, NYU Langone Health aims to contribute significantly to the advancement of medical knowledge and the enhancement of patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Howard B. Abikoff, PhD
Principal Investigator
C. Keith Conners
Principal Investigator
Laurence L. Greenhill, MD
Principal Investigator
Stephen P. Hinshaw, PhD
Principal Investigator
William E. Pelham, PhD
Principal Investigator
James M. Swanson, PhD
Principal Investigator
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials